Status:
UNKNOWN
Covid-19 Vaccination in Adolescents and Children
Lead Sponsor:
The University of Hong Kong
Conditions:
Covid19
Eligibility:
All Genders
Up to 100 years
Phase:
PHASE2
Brief Summary
Objectives To assess the reactogenicity, measure the adaptive immune responses and track the long-term immune memory in healthy children and adults as well as pediatric patients receiving the COVID-19...
Eligibility Criteria
Inclusion
- informed consent from the parents or a legally acceptable representative for an underage participant
- biological parents of students enrolled in the trial or unrelated healthy adults
- ability to adhere to the follow-up schedules
- willingness to report reactogenicity daily for 7 days post dose 1, 2 and 3 (and 4) proactively
- willingness to receive that vaccine available for that particular recruitment period (as student-parent pair, if applicable)
- good past health, including pre-existing clinically stable disease, such as paediatric or immune disorders
- prior COVID-19 (for COVID-19 survivor subgroup)
Exclusion
- 1\. reported pregnancy or breastfeeding
Key Trial Info
Start Date :
May 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2025
Estimated Enrollment :
1018 Patients enrolled
Trial Details
Trial ID
NCT04800133
Start Date
May 8 2021
End Date
March 31 2025
Last Update
January 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong, China